Kathera Bioscience Inc.
Union, NJ
- UEI
- SF26K1VYA5B9
- CAGE
- 8JCD6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1000 Morris Ave, Union, NJ 07083, USA
- Website
- katherabio.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Prokaryotics Incorporated | Union, NJ | 325411 Medicinal and Botanical Manufacturing |
| Quercus Molecular Design, LLC | Avon, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Aimmax Therapeutics Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Nubad LLC | Greer, SC | 541380 Testing Laboratories and Services |
| Curza Inc. | Salt Lake City, UT | — |
About the company
Kathera Bioscience Inc. is a for-profit corporation registered to receive federal grant awards since February 2020. The company specializes in developing novel antifungal drug candidates to address the global need for improved treatments of life-threatening fungal infections. Kathera's research focuses on identifying and targeting essential enzymes in pathogenic fungi to create broad-spectrum antifungal therapeutics that overcome limitations of current treatments such as drug resistance, toxicity, and narrow spectrum of activity.
Through multiple Project Grant awards from the National Institute of Allergy and Infectious Diseases (NIAID), Kathera Bioscience Inc. has pursued several research initiatives to advance antifungal drug discovery. These include developing fungal-selective dihydrofolate reductase (DHFR) inhibitors, creating a "Redesigning Existing Drugs Against Indispensable Targets" (REEDIT) platform to identify essential genes in pathogenic fungi, and investigating ESS1 as a novel antifungal target. The company's work aims to address critical gaps in current antifungal therapies by targeting new mechanisms of action, developing broad-spectrum drugs effective against multiple fungal pathogens, and overcoming issues of drug resistance. Kathera's research under these grants spans various stages of the drug discovery process, from target validation and hit identification to lead optimization and preclinical studies, with the long-term goal of advancing promising candidates towards clinical development.
Quick answers
Is Kathera Bioscience Inc. registered in SAM.gov?
Yes. Kathera Bioscience Inc.'s SAM.gov registration is active through May 26, 2027.
What is Kathera Bioscience Inc.'s most recent federal award?
Kathera Bioscience Inc.'s most recent federal grant award is Novel broad spectrum inhibitors of dihydrofolate reductase (dhfr) for treatment of infections from high threat fungal… (R44AI181163), from National Institute of Allergy and Infectious Diseases (NIH), on January 2, 2024.
On GovTribe
See Kathera Bioscience Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors